These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38102522)

  • 1. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
    Alduraibi FK; Singh JA
    Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.
    Popa CD; Opdam MAA; den Broeder N; van Ballegooijen H; Mulder K; van de Wiel KM; van Herwaarden N; Wientjes MHM; den Broeder AA
    Rheumatology (Oxford); 2024 Aug; 63(8):2142-2146. PubMed ID: 37796830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
    Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
    RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Cho SK; Kim H; Song YJ; Kim HW; Nam E; Lee SS; Lee HS; Park SH; Lee YA; Park MC; Chang SH; Kim HA; Kwok SK; Kim HR; Kim HS; Yoon BY; Uhm WS; Kim YG; Kim JH; Lee J; Choi J; Sung YK
    Korean J Intern Med; 2023 Jul; 38(4):546-556. PubMed ID: 37334513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
    Kwon OC; Choi W; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Park MC; Kim YG
    Adv Rheumatol; 2024 Apr; 64(1):26. PubMed ID: 38622706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
    Chen YW; Chen HH; Huang WN; Chen JP; Chen YH; Chen YM
    Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
    Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
    Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
    Palominos PE; Lineburger IB; Xavier RM
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
    Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
    Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated to long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population.
    Sebastiani M; Zabotti A; Biasi B; Cacioppo S; Sandri G; Giovannini I; Manfredi A; Quartuccio L
    Clin Exp Rheumatol; 2024 Jul; 42(7):1416-1420. PubMed ID: 38530664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis.
    Ebina K
    Mod Rheumatol; 2022 Feb; 32(2):256-262. PubMed ID: 34894239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study.
    Janak JC; Ross RD; Brady BL; Palmer L; Howard JT; Baker JF
    Arthritis Care Res (Hoboken); 2024 Sep; 76(9):1287-1293. PubMed ID: 38682605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.